Speech-Language Pathologists in Little Silver, NJ Accepting Medicare
5 Speech-Language Pathologists found. Showing 1 - 5
 Shore To Shore Communication Partners Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 24 Rosslyn Ct, Little Silver, NJ 07739 Phone: 908-309-2107 |
 Ms. Cynthia Anne Shotliff, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 17 Crest Dr, Little Silver, NJ 07739 Phone: 732-910-4074 |
Ms. Blair Allison Koczan, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 17 Crest Dr, Little Silver, NJ 07739 Phone: 732-996-6532 |
Jacqueline Diez, MS CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 53 Salem Lane, Little Silver, NJ 07739 Phone: 732-936-9151 |
Tammy Schlim Croak Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 302 Silverside Ave, Little Silver, NJ 07739 Phone: 609-658-7218 |
News Archive
New England Biolabs expands line of reagents for sample preparation
New England Biolabs has expanded its line of reagents for sample preparation upstream of next generation sequencing to include NEBNext® Small RNA Sample Prep Set 1 for sequencing on the Illumina® platforms, and NEBNext Small RNA Sample Prep Set 3 for sequencing on LIFE's SOLiD™ platform. These new products offer a new and unique protocol, which results in higher yields and lower adaptor-dimer formation, as compared to other protocols.
OBN, EMIG call on the UK government to allocate additional funding to support BMC programme
OBN and EMIG - organisations with a combined membership of approximately 570 emerging R&D companies in biotechnology and medical technology, and established small and mid-sized biopharmaceutical firms, respectively - have called on the UK government to allocate additional funding to support the industrial component of Innovate UK's Biomedical Catalyst (BMC).
Debating U.N. resolution on universal health coverage
Writing in the "UHC Forward" blog, Nkem Wellington, program officer at the Results for Development Institute (R4D), summarizes a debate that took place on the Performance-Based Financing Community of Practice online discussion forum following the December 12 U.N. General Assembly vote on the "Global health and foreign policy" draft resolution, which focused on universal health coverage (UHC).
Monoclonal antibody therapy achieves modest reduction in recurrence for patients with HER2-positive DCIS
The addition of the monoclonal antibody therapy Trastuzumab to radiotherapy did not reach the protocol objective of a 36% reduction in the ipsilateral breast tumor recurrence rate for women with HER2-positive ductal carcinoma in situ (DCIS) on the NRG Oncology clinical trial NSABP B-43.
› Verified 7 days ago
Physical Therapists
Chiropractors
Podiatrists
Speech-Language Pathologists
Optometrists
Occupational Therapists